Retatrutide (10 x vials)

Retatrutide (10 x vials)
CA$340.00

Retatrutide is an investigational medication developed by Eli Lilly for the treatment of obesity and type 2 diabetes. It is a unique triple agonist, meaning it simultaneously targets three different hormone receptors: GLP-1, GIP, and glucagon receptors. This multi-receptor approach aims to regulate blood sugar, suppress appetite, and enhance energy expenditure, making it highly effective for weight loss and diabetes management.

Uses of Retatrutide

  1. Obesity Treatment:

    • Weight Loss: In clinical trials, retatrutide has shown remarkable efficacy in promoting weight loss. Participants receiving higher doses experienced an average weight reduction of over 24% of their starting body weight within 48 weeks​ (Diabetes.org)​​ (SpringerLink)​.
    • Liver Health: Retatrutide has also demonstrated potential benefits for patients with nonalcoholic fatty liver disease (NAFLD), significantly reducing liver fat content and normalizing liver fat levels in most participants​ (Diabetes.org)​.

  2. Type 2 Diabetes Management:

    • Blood Sugar Control: By stimulating insulin release and reducing glucagon secretion, retatrutide helps maintain balanced blood glucose levels. This makes it a promising treatment option for managing type 2 diabetes​ (Peptide Sciences)​.
    • Insulin Sensitivity: It enhances the body’s response to insulin, thereby improving overall metabolic health and potentially preventing the progression of diabetes​ (Diabetes.org)​.

Mechanism of Action

Retatrutide works by:

  • GLP-1 Receptor Agonism: Stimulates insulin release in response to elevated blood glucose levels and suppresses glucagon secretion.
  • GIP Receptor Agonism: Enhances insulin secretion and has a role in appetite suppression.
  • Glucagon Receptor Agonism: Reduces the release of glucagon, aiding in lower blood glucose levels and supporting weight loss efforts​ (SpringerLink)​.

Clinical Trials and Future Prospects

Retatrutide is currently undergoing phase 3 clinical trials to further assess its efficacy and safety. If successful, it could become a significant addition to the available treatments for obesity and type 2 diabetes, providing a comprehensive approach to these interrelated conditions​ (Diabetes.org)​.

For more detailed information, you can refer to the American Diabetes Association and European Journal of Clinical Pharmacology.